IMUNON Announces First Participants Have Been Vaccinated In Its IMNN-101 Phase 1 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
IMUNON, Inc. (NASDAQ:IMNN) has announced that the first participants have been vaccinated in its IMNN-101 Phase 1 clinical trial. This study aims to demonstrate the potential of IMUNON's PlaCCine® platform as a next-generation DNA vaccine for seasonal COVID-19.
June 05, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IMUNON has initiated the Phase 1 clinical trial for its IMNN-101 DNA vaccine, which could validate its PlaCCine® platform as a next-generation COVID-19 vaccine.
The initiation of a Phase 1 clinical trial is a significant milestone for IMUNON, indicating progress in their vaccine development. Positive results could enhance the company's valuation and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100